Using AI-Guided Analytics in Early Stage Clinical Trials
The Pharmaceutical and Health IT fields have struggled to analyze the high volume and diverse types of molecular and clinical data currently available. In this regard, AI informed discovery presents a potential solution over the more traditional expert guided approaches. By favoring interpretability, continued method optimization and data flexibility, Berg Analytics has developed a data-driven and hypothesis-free AI solution that has been successfully utilized to generate actionable outcomes in both clinical development and healthcare fields. In an effort to take advantage of both probabilistic and neural net-based AI technologies, Berg Analytics is currently exploring methods to augment these deep-learning methods.
Dr. Eric Milliman, Ph.D. is a Data Scientist at Berg Analytics, a division of Berg Pharma, where he works on researching, developing and applying innovative data-driven methods in the de-novo discovery of therapeutics and biomarkers. Prior to his role at Berg, Dr. Milliman was a post-doctoral fellow in the Epigenetics & Stem Cell Biology Laboratory at the National Institute of Environmental Health Sciences. Dr. Milliman holds a Ph.D. in Biology from the State University of New York at Buffalo.